LCD-DL40249
Document details
Summary
The proposed LCD on molecular testing for solid organ allograft rejection could significantly affect billing practices by defining specific guidelines for necessary tests and circumstances under whichNew LCD could impact solid organ testing reimbursements.
Affected specialty
Transplantation alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=40248&ver=2CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy LCD-L38582 · Transplantation
The implementation of the MolDX molecular testing for solid organ allograft rejection will enhance the ability to detect potential organ rejection, impacting billing through the adoption of new HCPCS
View alertPolicy LCD-L38671 · Transplantation
The new LCD on molecular testing for solid organ allograft rejection will impact billing practices by introducing specific guidelines for coverage and documentation requirements. Providers need to adj
View alertPolicy LCD-L39396 · Hematology
The coverage policy for allogeneic hematopoietic cell transplantation in treating primary refractory or relapsed Hodgkin's and Non-Hodgkin's lymphomas may significantly impact billing practices, as th
View alertPolicy LCD-L39434 · Hematology
The new LCD will impact billing for allogeneic hematopoietic cell transplantation procedures in patients with primary refractory or relapsed lymphoma. Providers should ensure proper coding and documen
View alert